Signals, Powered By EquityPandit
A warning letter has been issued by the US Food and Drug Administration (USFDA) to Wockhardt for violation of current good manufacturing practice norms that includes its failure for ensuring proper clothing for workers at its Ankleshwar plant in Gujarat.
The USFDA has said in a letter to Wockhardt Chairman and Group CEO Habil Khorakiwala that the inspectors have found during the inspection from from December 7 to 15, 2015, “significant violations” of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals as well as for active pharmaceutical ingredients (API).
